BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hagiwara S, Kudo M, Kawasaki T, Nagashima M, Minami Y, Chung H, Fukunaga T, Kitano M, Nakatani T. Prognostic factors for portal venous invasion in patients with hepatocellular carcinoma. J Gastroenterol. 2006;41:1214-1219. [PMID: 17287901 DOI: 10.1007/s00535-006-1950-7] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Chang IS, Shin SW, Cho SK, Rhim H, Choi D, Park KB, Park HS, Choo SW, Do YS, Choo I. Evolution of portal vein tumor thromboses in patients with hepatocellular carcinoma: CT findings and transition of serum tumor markers. Clinical Imaging 2012;36:489-95. [DOI: 10.1016/j.clinimag.2011.11.020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
2 Akkiz H, Carr BI, Kuran S, Karaoğullarından Ü, Üsküdar O, Tokmak S, Arslan B, Doran F, Balli HT, Ülkü A, Akçam TA, Bahçeci Hİ, Polat KY, Örmeci N, Şimşek H, Sonsuz A, Demir A, Altıntaş E, Demir M, Yalçın K, Ekinci N, Harmancı Özakyol A, Yücesoy M, Uygun A, Guerra V, Delik A, Tokat Y, Yilmaz S, Bektaş A, Kılıç M. Macroscopic Portal Vein Thrombosis in HCC Patients. Can J Gastroenterol Hepatol. 2018;2018:3120185. [PMID: 30009156 DOI: 10.1155/2018/3120185] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
3 Beale G, Chattopadhyay D, Gray J, Stewart S, Hudson M, Day C, Trerotoli P, Giannelli G, Manas D, Reeves H. AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease. BMC Cancer 2008;8:200. [PMID: 18638391 DOI: 10.1186/1471-2407-8-200] [Cited by in Crossref: 83] [Cited by in F6Publishing: 79] [Article Influence: 5.9] [Reference Citation Analysis]
4 Yang M, Zhang X, Liu J. Prognostic value of des-γ-carboxy prothrombin in patients with hepatocellular carcinoma treated with transarterial chemotherapy: A systematic review and meta-analysis. PLoS One 2019;14:e0225170. [PMID: 31730646 DOI: 10.1371/journal.pone.0225170] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
5 Choi JY, Jung SW, Kim HY, Kim M, Kim Y, Kim DG, Oh EJ. Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP. World J Gastroenterol 2013; 19(3): 339-346 [PMID: 23372355 DOI: 10.3748/wjg.v19.i3.339] [Cited by in CrossRef: 53] [Cited by in F6Publishing: 49] [Article Influence: 5.9] [Reference Citation Analysis]
6 Zeng ZC, Fan J, Tang ZY, Zhou J, Wang JH, Wang BL, Guo W. Prognostic factors for patients with hepatocellular carcinoma with macroscopic portal vein or inferior vena cava tumor thrombi receiving external-beam radiation therapy. Cancer Sci. 2008;99:2510-2517. [PMID: 19032365 DOI: 10.1111/j.1349-7006.2008.00981.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
7 Arai T, Kobayashi A, Ohya A, Takahashi M, Yokoyama T, Shimizu A, Motoyama H, Furusawa N, Notake T, Kitagawa N. Assessment of treatment outcomes based on tumor marker trends in patients with recurrent hepatocellular carcinoma undergoing trans-catheter arterial chemo-embolization. Int J Clin Oncol. 2014;19:871-879. [PMID: 24218280 DOI: 10.1007/s10147-013-0634-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
8 Zhang Z, Zhang Y, Wang W, Hua Y, Liu L, Shen S, Peng B. Thrombocytopenia and the outcomes of hepatectomy for hepatocellular carcinoma: a meta-analysis. J Surg Res. 2017;210:99-107. [PMID: 28457347 DOI: 10.1016/j.jss.2016.11.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
9 Bae HM, Lee JH, Yoon JH, Kim YJ, Heo DS, Lee HS. Protein induced by vitamin K absence or antagonist-II production is a strong predictive marker for extrahepatic metastases in early hepatocellular carcinoma: a prospective evaluation. BMC Cancer. 2011;11:435. [PMID: 21985636 DOI: 10.1186/1471-2407-11-435] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
10 Masuda T, Miyoshi E. Cancer biomarkers for hepatocellular carcinomas: from traditional markers to recent topics. Clin Chem Lab Med 2011;49:959-66. [PMID: 21428856 DOI: 10.1515/CCLM.2011.152] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
11 Gomaa AI, Khan SA, Leen EL, Waked I, Taylor-Robinson SD. Diagnosis of hepatocellular carcinoma. World J Gastroenterol 2009; 15(11): 1301-1314 [PMID: 19294759 DOI: 10.3748/wjg.15.1301] [Cited by in CrossRef: 104] [Cited by in F6Publishing: 87] [Article Influence: 8.0] [Reference Citation Analysis]
12 Bertino G, Ardiri A, Malaguarnera M, Malaguarnera G, Bertino N, Calvagno GS. Hepatocellualar carcinoma serum markers. Semin Oncol. 2012;39:410-433. [PMID: 22846859 DOI: 10.1053/j.seminoncol.2012.05.001] [Cited by in Crossref: 103] [Cited by in F6Publishing: 101] [Article Influence: 10.3] [Reference Citation Analysis]
13 Cura M, Cura A, Suri R, El-Merhi F, Lopera J, Kroma G. Causes of TIPS dysfunction. AJR Am J Roentgenol. 2008;191:1751-1757. [PMID: 19020247 DOI: 10.2214/ajr.07.3534] [Cited by in Crossref: 52] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
14 Mori Y, Tamai H, Shingaki N, Moribata K, Shiraki T, Deguchi H, Ueda K, Enomoto S, Magari H, Inoue I. Diffuse intrahepatic recurrence after percutaneous radiofrequency ablation for solitary and small hepatocellular carcinoma. Hepatol Int. 2009;3:509-515. [PMID: 19669252 DOI: 10.1007/s12072-009-9131-4] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
15 Yamamoto K, Imamura H, Matsuyama Y, Hasegawa K, Beck Y, Sugawara Y, Makuuchi M, Kokudo N. Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy. Ann Surg Oncol. 2009;16:2795-2804. [PMID: 19669841 DOI: 10.1245/s10434-009-0618-y] [Cited by in Crossref: 74] [Cited by in F6Publishing: 78] [Article Influence: 5.7] [Reference Citation Analysis]
16 Rim CH, Kim HJ, Seong J. Clinical feasibility and efficacy of stereotactic body radiotherapy for hepatocellular carcinoma: A systematic review and meta-analysis of observational studies. Radiother Oncol. 2019;131:135-144. [PMID: 30773180 DOI: 10.1016/j.radonc.2018.12.005] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 11.0] [Reference Citation Analysis]
17 Dufour JF, Johnson P. Liver cancer: from molecular pathogenesis to new therapies: summary of the EASL single topic conference. J Hepatol 2010;52:296-304. [PMID: 20006399 DOI: 10.1016/j.jhep.2009.11.010] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
18 Inagaki Y, Tang W, Makuuchi M, Hasegawa K, Sugawara Y, Kokudo N. Clinical and molecular insights into the hepatocellular carcinoma tumour marker des-γ-carboxyprothrombin. Liver Int. 2011;31:22-35. [PMID: 20874725 DOI: 10.1111/j.1478-3231.2010.02348.x] [Cited by in Crossref: 66] [Cited by in F6Publishing: 59] [Article Influence: 5.5] [Reference Citation Analysis]
19 Takeji S, Hirooka M, Koizumi Y, Tokumoto Y, Abe M, Ikeda Y, Nadano S, Hiasa Y, Onji M. Des-gamma-carboxy prothrombin identified by P-11 and P-16 antibodies reflects prognosis for patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2013;28:671-7. [PMID: 23215762 DOI: 10.1111/jgh.12076] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
20 Taketomi A, Sanefuji K, Soejima Y, Yoshizumi T, Uhciyama H, Ikegami T, Harada N, Yamashita Y, Sugimachi K, Kayashima H, Iguchi T, Maehara Y. Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation. Transplantation. 2009;87:531-537. [PMID: 19307789 DOI: 10.1097/tp.0b013e3181943bee] [Cited by in Crossref: 113] [Cited by in F6Publishing: 41] [Article Influence: 8.7] [Reference Citation Analysis]
21 Abu El Makarem M. An overview of biomarkers for the diagnosis of hepatocellular carcinoma. Hepat Mon 2012;12:e6122. [PMID: 23162601 DOI: 10.5812/hepatmon.6122] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
22 Pang Q, Qu K, Bi JB, Liu SS, Zhang JY, Song SD, Lin T, Xu XS, Wan Y, Tai MH, Liu HC, Dong YF, Liu C. Thrombocytopenia for prediction of hepatocellular carcinoma recurrence: Systematic review and meta-analysis. World J Gastroenterol 2015; 21(25): 7895-7906 [PMID: 26167090 DOI: 10.3748/wjg.v21.i25.7895] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
23 Kimura H, Ohkawa K, Miyazaki M, Sakakibara M, Imanaka K, Tamura T, Sueyoshi H, Takada R, Fukutake N, Uehara H, Ashida R, Ioka T, Nakazawa T, Nakanishi K, Katayama K. Subclassification of patients with intermediate-stage (Barcelona Clinic Liver Cancer stage-B) hepatocellular carcinoma using the up-to-seven criteria and serum tumor markers. Hepatol Int. 2017;11:105-114. [PMID: 27766479 DOI: 10.1007/s12072-016-9771-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
24 Pang Q, Qu K, Zhang JY, Song SD, Liu SS, Tai MH, Liu HC, Liu C. The Prognostic Value of Platelet Count in Patients With Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Medicine (Baltimore) 2015;94:e1431. [PMID: 26376382 DOI: 10.1097/MD.0000000000001431] [Cited by in Crossref: 47] [Cited by in F6Publishing: 27] [Article Influence: 6.7] [Reference Citation Analysis]
25 Carr BI, Guerra V, Donghia R, Yilmaz S. Tumor multifocality and serum albumin levels can identify groups of patients with hepatocellular carcinoma and portal vein thrombosis having distinct survival outcomes. Ann Med Surg (Lond) 2021;66:102458. [PMID: 34141428 DOI: 10.1016/j.amsu.2021.102458] [Reference Citation Analysis]
26 Shariff MI, Cox IJ, Gomaa AI, Khan SA, Gedroyc W, Taylor-robinson SD. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Review of Gastroenterology & Hepatology 2014;3:353-67. [DOI: 10.1586/egh.09.35] [Cited by in Crossref: 197] [Cited by in F6Publishing: 194] [Article Influence: 24.6] [Reference Citation Analysis]
27 Hanaoka T, Sato S, Tobita H, Miyake T, Ishihara S, Akagi S, Amano Y, Kinoshita Y. Clinical significance of the highly sensitive fucosylated fraction of α-fetoprotein in patients with chronic liver disease. J Gastroenterol Hepatol. 2011;26:739-744. [PMID: 21083609 DOI: 10.1111/j.1440-1746.2010.06585.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
28 Lee S, Rhim H, Kim YS, Kang TW, Song KD. Post-ablation des-gamma-carboxy prothrombin level predicts prognosis in hepatitis B-related hepatocellular carcinoma. Liver Int 2016;36:580-7. [PMID: 26503910 DOI: 10.1111/liv.12991] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
29 Azumi M, Suda T, Terai S, Akazawa K. Prognostic Impact of Indocyanine Green Plasma Disappearance Rate in Hepatocellular Carcinoma Patients after Radiofrequency Ablation: A Prognostic Nomogram Study. Intern Med 2017;56:1001-7. [PMID: 28458303 DOI: 10.2169/internalmedicine.56.7278] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
30 Hakamada K, Kimura N, Miura T, Morohashi H, Ishido K, Nara M, Toyoki Y, Narumi S, Sasaki M. Des-gamma-carboxy prothrombin as an important prognostic indicator in patients with small hepatocellular carcinoma. World J Gastroenterol 2008; 14(9): 1370-1377 [PMID: 18322950 DOI: 10.3748/wjg.14.1370] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
31 Kim JM, Kwon CH, Joh JW, Ko JS, Park JB, Lee JH, Kim SJ, Paik SW, Park CK. C-reactive protein may be a prognostic factor in hepatocellular carcinoma with malignant portal vein invasion. World J Surg Oncol. 2013;11:92. [PMID: 23618082 DOI: 10.1186/1477-7819-11-92] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
32 Carr BI, Guerra V. Low Alpha-Fetoprotein Levels Are Associated with Improved Survival in Hepatocellular Carcinoma Patients with Portal Vein Thrombosis. Dig Dis Sci 2016;61:937-47. [PMID: 26576554 DOI: 10.1007/s10620-015-3922-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
33 Carr BI, Guerra V, Donghia R. Portal Vein Thrombosis and Markers of Inflammation in Hepatocellular Carcinoma. J Gastrointest Cancer 2020;51:1141-7. [PMID: 32851544 DOI: 10.1007/s12029-020-00489-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
34 Chen JS, Wang Q, Chen XL, Huang XH, Liang LJ, Lei J, Huang JQ, Li DM, Cheng ZX. Clinicopathologic characteristics and surgical outcomes of hepatocellular carcinoma with portal vein tumor thrombosis. J Surg Res. 2012;175:243-250. [PMID: 21601221 DOI: 10.1016/j.jss.2011.03.072] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
35 Matsubara M, Shiraha H, Kataoka J, Iwamuro M, Horiguchi S, Nishina S, Takaoka N, Uemura M, Takaki A, Nakamura S. Des-γ-carboxyl prothrombin is associated with tumor angiogenesis in hepatocellular carcinoma. J Gastroenterol Hepatol. 2012;27:1602-1608. [PMID: 22554292 DOI: 10.1111/j.1440-1746.2012.07173.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
36 Chon YE, Choi GH, Lee MH, Kim SU, Kim do Y, Ahn SH, Kim KS, Choi JS, Han KH, Chon CY. Combined measurement of preoperative α-fetoprotein and des-γ-carboxy prothrombin predicts recurrence after curative resection in patients with hepatitis-B-related hepatocellular carcinoma. Int J Cancer. 2012;131:2332-2341. [PMID: 22362471 DOI: 10.1002/ijc.27507] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]